Covered recipient · General Payments record
ADIANYS OBREGON RODRIGUEZ
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2024
$317.55
- Reported across 16 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $317.55 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| QOL Medical, LLC | $85.36 | 5 |
| ABBVIE INC. | $63.01 | 3 |
| Gilead Sciences, Inc. | $56.86 | 2 |
| EVOKE PHARMA, INC. | $36.63 | 2 |
| Celltrion USA Inc. | $24.45 | 1 |
| Lilly USA, LLC | $21.49 | 1 |
| Braintree Laboratories, Inc. | $15.41 | 1 |
| AIMMUNE THERAPEUTICS, INC. | $14.34 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2024 | $317.55 | 16 |
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.87 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107755072 | CMS |
| ABBVIE INC. | $23.29 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107755074 | CMS |
| ABBVIE INC. | $21.85 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107755076 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $14.34 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146960317 | CMS |
| Braintree Laboratories, Inc. | $15.41 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125521808 | CMS |
| Celltrion USA Inc. | $24.45 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1075865707 | CMS |
| EVOKE PHARMA, INC. | $20.78 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127779675 | CMS |
| EVOKE PHARMA, INC. | $15.85 | 11/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127780091 | CMS |
| Gilead Sciences, Inc. | $32.93 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133648310 | CMS |
| Gilead Sciences, Inc. | $23.93 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133648312 | CMS |
| Lilly USA, LLC | $21.49 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135494416 | CMS |
| QOL Medical, LLC | $17.25 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147738958 | CMS |
| QOL Medical, LLC | $15.47 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147738960 | CMS |
| QOL Medical, LLC | $16.97 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147738962 | CMS |
| QOL Medical, LLC | $14.85 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147738964 | CMS |
| QOL Medical, LLC | $20.82 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147738966 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2024
- Source files
- Dataset page · Bulk file · PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.